To see the other types of publications on this topic, follow the link: National Advisory Committee on Education.
Journal articles on the topic 'National Advisory Committee on Education'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'National Advisory Committee on Education.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Mittler, Peter. "Editorial: A National Advisory Committee for Special Educational Needs?" British Journal of Special Education 11, no. 3 (May 31, 2007): 5. http://dx.doi.org/10.1111/j.1467-8578.1984.tb00229.x.
Full text
2
Herwan, Herwan, Aswandi Aswandi, and M. Chiar. "The Role of School Committee in Supporting The Fulfillment of Education Facilities and Infrastructure." JETL (Journal Of Education, Teaching and Learning) 3, no. 2 (September 1, 2018): 282. http://dx.doi.org/10.26737/jetl.v3i2.763.
Full textAbstract:
<p>This study aims to determine the role of school committees in supporting the fulfillment of educational infrastructure facilities at State Vocational High School 1 Teluk Keramat (SMKN 1 Teluk Keramat) by identifying and describing the role and involvement and form of support provided and the factors that influence it. This research uses qualitative descriptive approach. the results of the research that has been done are 1) School Committee SMKN 1 Teluk Keramat has performed its role as an advisory agency, as a supporter agency, as a controlling agency, and as mediator agency; 2) Supporting factors for the school committee include a) Good collaboration of schools; b) Authority granted by the school to the school committee in carrying out its duties; c) Compulsory responsibility of completing the compulsory education of 12 years of learners; d) To carry out the mandate of the Law on National Education System Number 20 of 2003 and Permendikbud Number 75 concerning School Committees; 3) Inhibiting factors for school committees are a) Lack of coordination between schools and school committees; b) Be more concerned with personal matters than school committee duties; c) lack of awards earned as school committees; d) Ineffective committee managers due to the distance from schools; 4) Not all school committee members are actively involved.</p>
3
Mulondo, Mutshidzi A., Joyce M. Tsoka-Gwegweni, Puleng LenkaBula, and Perpetual Chikobvu. "A Survey to Determine the Capacity Development Needs of Research Ethics Committee Administrators in South Africa." Journal of Empirical Research on Human Research Ethics 17, no. 1-2 (November 22, 2021): 84–93. http://dx.doi.org/10.1177/15562646211056762.
Full textAbstract:
Most capacity development efforts for research ethics committees focus on committee members and little on ethics administrators. Increasing studies mandate the focus on administrators’ capacity development needs to enable adequate and effective committee support. This study investigated current responsibilities, training requirements, and administrator role needs. An online cross-sectional survey was conducted among administrators from 62 National Health Research Ethics Council-registered research ethics committees in South Africa. In total, 36 administrators completed the questionnaire. Results show that, in addition to administration, they perform managerial, review process and guidance-advisory tasks. Nearly 49% indicated only having received informal research ethics-related training, not targeted formal training, with 81% of the informal training being through workshops. Research ethics administrators’ responsibilities have evolved to complex tasks requiring targeted capacity development efforts.
4
Roter, Petra. "Minority Children and Education in the Work of the Advisory Committee." International Journal on Minority and Group Rights 22, no. 2 (May 26, 2015): 202–31. http://dx.doi.org/10.1163/15718115-02202004.
Full textAbstract:
This article seeks to analyse the relevance of the Framework Convention for the Protection of National Minorities (Framework Convention) for minority children in the field of education. It does this with a comprehensive analysis of primary sources, namely opinions of the Framework Convention’s Advisory Committee, which monitors the treaty’s implementation. The article therefore also analyses the role of this independent monitoring body in protecting minority children’s rights. It argues that the Framework Convention provides a very relevant structure for children’s rights, and demonstrates that perhaps the most valuable contribution of the Advisory Committee to the field of children’s rights has been, firstly, in identifying various obstacles that are preventing the full implementation of children’s rights in the field of education; secondly, in recommending measures for removing those obstacles or mitigating their effects; and, thirdly, in identifying best practices with regards to the rights of children to education.
5
Sahler, Olle Jane, David Babbott, Susan Day, Julia McMillan, Barbara Schuster, Gary Gugelchuk, Robert Davidson, and Lewis R. First. "What Did We Learn about National Organizational Collaboration at the Advisory Committee Level?" Academic Medicine 76, Supplement (April 2001): S43—S48. http://dx.doi.org/10.1097/00001888-200104001-00009.
Full text
6
Sam, Joel. "National Bibliography in Ghana." African Research & Documentation 75 (1997): 5–11. http://dx.doi.org/10.1017/s0305862x00016058.
Full textAbstract:
Various governments of Ghana have, at least on paper, shown recognition of the need for a national library, which will undertake as one of its principal responsibilities the preparation of the national bibliography. In January 1963, for example, the Ministry of Education set up a Technical Advisory Committee to advise on the need for a national library. The Committee had several sittings and it did succeed in submitting proposals to obtain some financial support if not for the building of a national library then, at least, for developing some of its functions, including the publication of retrospective and current national bibliographies.Earlier in 1961, the George Padmore Research Library on African Affairs (GPRLAA) had been established by Dr Kwame Nkrumah, former President of Ghana, in memory of his friend, the late George Padmore, with the objective of providing a centre for the study of African affairs in Ghana.
7
Shin, Hyun-Seok, and Sang Hoon Choi. "Reevaluating the Governance of the National Education Commission and Exploring Strategies to Enhance Public Participation." Korea Society Of The Politics Of Education 30, no. 4 (December 31, 2023): 211–43. http://dx.doi.org/10.52183/kspe.2023.30.4.211.
Full textAbstract:
This study explores strategies for the National Education Commission to function as a cooperative educational governance for expanded citizen participation. The governance model is divided into structural (involving a National Participation Committee at the central level and a regional educational governance at the local level) and process-oriented (involving a Public Deliberation Committee and a social consultation model). Analyzing the models, the study focuses on the degree of hierarchical organization and organizational organization of understanding groups. The National Participation Committee exhibits cooperative governance with low organizational organization of understanding groups, requiring consideration of advisory body limitations and ways to incorporate field voices. Regional educational governance shows a hierarchical form, necessitating attention to network configuration to avoid operation by compromise rather than stakeholder participation. Both the Public Deliberation Committee and the social consultation model have cooperative governance, but differences in organizational organization and hierarchical structure suggest the need for specialized mechanisms based on issue characteristics. Overall, the study suggests improvements for each model to optimize citizen participation and cooperation in educational governance.
8
Swing, Susan R., Stephen G. Clyman, Eric S. Holmboe, and Reed G. Williams. "Advancing Resident Assessment in Graduate Medical Education." Journal of Graduate Medical Education 1, no. 2 (December 1, 2009): 278–86. http://dx.doi.org/10.4300/jgme-d-09-00010.1.
Full textAbstract:
Abstract Background The Outcome Project requires high-quality assessment approaches to provide reliable and valid judgments of the attainment of competencies deemed important for physician practice. Intervention The Accreditation Council for Graduate Medical Education (ACGME) convened the Advisory Committee on Educational Outcome Assessment in 2007–2008 to identify high-quality assessment methods. The assessments selected by this body would form a core set that could be used by all programs in a specialty to assess resident performance and enable initial steps toward establishing national specialty databases of program performance. The committee identified a small set of methods for provisional use and further evaluation. It also developed frameworks and processes to support the ongoing evaluation of methods and the longer-term enhancement of assessment in graduate medical education. Outcome The committee constructed a set of standards, a methodology for applying the standards, and grading rules for their review of assessment method quality. It developed a simple report card for displaying grades on each standard and an overall grade for each method reviewed. It also described an assessment system of factors that influence assessment quality. The committee proposed a coordinated, national-level infrastructure to support enhancements to assessment, including method development and assessor training. It recommended the establishment of a new assessment review group to continue its work of evaluating assessment methods. The committee delivered a report summarizing its activities and 5 related recommendations for implementation to the ACGME Board in September 2008.
9
Cai, Jinfa. "Editorial: The Evolving Practice of Scholarly Book Reviews." Journal for Research in Mathematics Education 46, no. 3 (May 2015): 250–52. http://dx.doi.org/10.5951/jresematheduc.46.3.0250.
Full textAbstract:
Although the Journal for Research in Mathematics Education (JRME)published its first issue in January of 1970, the first scholarly book review appeared in the January 1977 issue under the editorship of James Wilson. In it, Thomas Kieren (1977) reviewed the 1975 National Advisory Committee on Mathematical Education (NACOME) report,Overview and Analysis of School Mathematics Grades K–12.In his editorial for the issue, Wilson (1977) wrote,
10
Glidden, Peter L. "Soundoff: How National Examinations Can Benefit Students and Teachers." Mathematics Teacher 85, no. 8 (November 1992): 610–11. http://dx.doi.org/10.5951/mt.85.8.0610.
Full textAbstract:
Several reform groups, including the President's Education Policy Advisory Committee and Educate America, are calling for national examinations for high school students. Examination advocates claim the following benefits: the establishment of national standards, increased accountability, and increased motivation for students. Advocates also point out that the United States is the only major industrialized country without some sort of national examination. Critics claim that examinations restrict teachers' creativity; force teachers to teach for the examination; and promote improper comparisons among states, districts, schools, teachers, and students. (See, e.g., DeWitt [1991]).
11
Thorman, Jan C., and Charles G. Groat. "Review of Analyses of the Exxon Valdez Oil Spill by the Policy Committee of the OCS Advisory Board1." International Oil Spill Conference Proceedings 1991, no. 1 (March 1, 1991): 285–89. http://dx.doi.org/10.7901/2169-3358-1991-1-285.
Full textAbstract:
ABSTRACT On May 23, 1990, the Policy Committee of the Outer Continental Shelf Advisory Board approved a report containing 24 recommendations. These recommendations are intended to help develop a credible national oil spill prevention and response program for both OCS and non-OCS spills in the marine environment. The committee concluded that such a program is needed to improve public confidence and foster the public support necessary for a viable OCS oil and gas program in the wake of the Exxon Valdez oil spill. Eight essential elements of such a program were identified, and recommendations addressing these elements were presented in the report. This paper focuses on recommendations dealing with command of oil spill response and public involvement and education in oversight of oil spill prevention efforts, contingency planning, and spill response. A subcommittee of the Policy Committee is pursuing the implementation of the recommendations in the report, focusing on Minerals Management Service actions and the extent to which the Oil Pollution Act of 1990 addresses the committee's recommendations.
12
Powell, Martin. "The lost worlds of royal commissions in the NHS: The unaccountable in pursuit of the unanswerable?" Teaching Public Administration 37, no. 2 (March 5, 2019): 199–217. http://dx.doi.org/10.1177/0144739419830449.
Full textAbstract:
There have been recent calls for a royal commission (RC) on the British National Health Service (NHS). This article focuses on the impact of RCs and similar advisory bodies, particularly on finance recommendations, of three inquiries with broad remits across the whole of the NHS from very different periods: Guillebaud (1956); Royal Commission on the National Health Service (1979); and House of Lords Select Committee on the Long-term Sustainability of the NHS (2017). These inquiries appear to have had rather limited impacts, especially on NHS funding. First, there appears to be some hesitancy in suggesting precise figures for NHS expenditure. Second, the reports are advisory, and governments can ignore their conclusions. Third, governments have ignored their conclusions. In the 1950s and the 1980s, contrary to the recommendations of the inquiries, NHS expenditure subsequently grew only slowly, and charges were increased. In short, asking an independent RC to provide answers on NHS expenditure is perhaps the unaccountable in pursuit of the unanswerable.
13
Fisher, Charles W. "Review: The Research Agenda Project as Prologue." Journal for Research in Mathematics Education 21, no. 1 (January 1990): 81–89. http://dx.doi.org/10.5951/jresematheduc.21.1.0081.
Full textAbstract:
There may be good news for precollege mathematics. For those who are alarmed by recent results of the National Assessment of Educational Progress, the widening gap between supply and demand for mathematically literate graduates (including new mathematics teachers), and discouraging comparisons in international studies, this possibility may come as a surprise. The good news comes in the form of the Research Agenda Project (RAP) for mathematics education that was conceived and implemented by NCTM's Research Advisory Committee.
14
Norback, Judith Shaul, and Diane Wattay. "Job Analysis of the Knowledge Important for Newly Licensed Physical Education Teachers." Journal of Teaching in Physical Education 14, no. 1 (October 1994): 60–84. http://dx.doi.org/10.1123/jtpe.14.1.60.
Full textAbstract:
A job analysis was conducted to develop specifications for the physical education assessment of The Praxis Series: Professional Assessments for Beginning Teachers and to support the content relevance of the assessment. An advisory committee consisting of physical education teachers, teacher educators, and administrators worked with measurement psychologists to describe a knowledge domain important for newly licensed/certified physical education teachers to perform their jobs competently. The knowledge areas were judged for importance by a national sample of 815 physical education teachers, administrators, and college faculty. As a result of this survey, 128 knowledge statements were judged as important for newly licensed/certified physical education teachers.
15
Hetherington, Norriss S. "The National Advisory Committee for Aeronautics: A forerunner of federal governmental support for scientific research." Minerva 28, no. 1 (1990): 59–80. http://dx.doi.org/10.1007/bf01096326.
Full text
16
Cohen, Dermot P. "National audit of higher training posts in child and adolescent psychiatry in Ireland." Psychiatrist 34, no. 8 (August 2010): 351–53. http://dx.doi.org/10.1192/pb.bp.109.028191.
Full textAbstract:
Aims and methodThe audit aimed to assess current senior registrar posts in child and adolescent psychiatry in Ireland in terms of working environment, conditions and training issues. The posts were compared with standards set down by the Child and Adolescent Psychiatry Specialist Advisory Committee of the Royal College of Psychiatrists and the National Higher Training Subcommittee of the Irish Psychiatric Training Committee.ResultsThe audit cycle was completed twice and a 100% response rate was achieved on both occasions.Clinical implicationsHigher training posts in child and adolescent psychiatry in Ireland compare favourably to standards for training and education, but poorly for working environment, case-load and educational supervision.
17
Wright, Gillian. "Animal Production - a case study of consumer reaction with special reference to the diet and health issue." Proceedings of the British Society of Animal Production (1972) 1988 (March 1988): 72. http://dx.doi.org/10.1017/s0308229600017104.
Full textAbstract:
Healthy eating is now a feature of the strategies of many organisations in the food industry. This has developed since the recommendations of the NACNE (National Advisory Committee on Nutrition Education) report, and COMA (Committee on Medical Aspects of Food Policy) report on cardiovascular disease were published. These led to considerable media coverage and stimulated consumer demand for healthy choices in their shopping. This research is concerned with the consumer reaction to dietary recommendations, using milk as a case study. The increased interest in diet and health can be demonstrated by the increased market share of some food products: wholemeal bread now accounts for 25% of bread sales and low fat milks for over 20% of total milk sales.
18
Browarek, Tomasz. "The Situation of the Roma in Poland in the Opinions of the Advisory Committee and the Committee of Experts of the Council of Europe." Annales Universitatis Mariae Curie-Skłodowska sectio K – Politologia 30, no. 1 (October 25, 2023): 47–59. http://dx.doi.org/10.17951/k.2023.30.1.47-59.
Full textAbstract:
The main objective of this article is to analyze the situation of the Roma minority in Poland, by presenting its economic situation, access to education, implementation of language rights and the degree of implementation of the principles of equal treatment and prohibition of discrimination in relation to this community. The basis for this is the analysis of the opinions of the Council of Europe Advisory Committee on the Framework Convention for the Protection of National Minorities and the reports of the Committee of Experts on the European Charter for Regional or Minority Languages. The main thesis of the work is the statement that in the analyzed period there was an improvement in the situation of the Roma minority in terms of access to education, living conditions and the implementation of language rights. However, the Roma minority is still perceived negatively in Polish society and there are cases of discrimination against it.
19
Harvey, John G. "Teaching Mathematics With Technology: Using Calculators in Mathematics Changes Testing." Arithmetic Teacher 38, no. 7 (March 1991): 52–54. http://dx.doi.org/10.5951/at.38.7.0052.
Full textAbstract:
No matter the level at which we teach mathematics, we are being asked to incorporate calculators into our instruction, to teach students both calculator facility and effective ways of using calculators, and to encourage and expect those students to use calculators appropriately. As early as 1975, just three years after the introduction of Texas Instruments's Data Math calculator, the National Advisory Committee on Mathematical Education (NACOME) urged that calculators be used in mathematics instruction (NACOME 1975, 40–43). Five years later the National Council of Teachers of Mathematics recommended that “mathematics programs [should] take full advantage of calculators … at all grade levels” (NCTM 1980, 1).
20
Sheppard, Josh. "The Political Economic Structure of Early Media Reform Before and After the Communications Act of 1934." Resonance 1, no. 3 (2020): 244–66. http://dx.doi.org/10.1525/res.2020.1.3.244.
Full textAbstract:
This paper examines how early media reform work evolved from political activism into a system-building advocacy campaign in support of Schools of the Air between 1930 and 1940. Calling upon archival work that focuses on 1935–1940 records, it examines how prominent activist groups the National Committee for Education by Radio (NCER) and the National Advisory Council for Radio in Education (NACRE) shifted their strategic approaches to adjust to the “public interest” mandate of the Communications Act of 1934. Though scholarship has chronicled disagreements between the NCER and NACRE over how to best support educational broadcasting, a dialectical interplay emerged after the act during the New Deal due to the influence of the Federal Radio Education Committee (FREC). FREC inspired A.G. Crane of the NCER to build the Rocky Mountain Radio Council (RMRC). The RMRC was the first sustainable educational media network, and the group coined the term public broadcasting. While the Communications Act signaled the end of the first wave of media activism, the policy also inspired reformers to develop a new system-building strategy that set the groundwork for NPR and PBS.
21
Setiawan, F., R. L. Toruan, L. Subehi, and A. Rahmat. "The 5th Indonesian Society of Limnology (MLI) Congress and International Conference 2021." IOP Conference Series: Earth and Environmental Science 1062, no. 1 (July 1, 2022): 011001. http://dx.doi.org/10.1088/1755-1315/1062/1/011001.
Full textAbstract:
The 5th Indonesian Society of Limnology (MLI) Congress and International Conference 2021 is a biannual conference organized by the Indonesian Society of Limnology, with the theme is “Building synergies towards sustainable use of inland waters.” This year due to the COVID-19 pandemic, we hold the event virtually from 2nd to 3rd December. The objectives of this event are to (1) Connect, discuss, share and create a mutual network among communities from different backgrounds who are interested in inland waters ecosystem; (2) Disseminate science & technology and lessen the gap between scientific and common communities through fruitful discussion settings; (3) Underpin sustainable use and management of inland aquatic ecosystems. There were four keynotes speakers, four invited speakers, and 66 general presenters in the conference sessions. In total, 116 participants were registered and joined the conference. The first keynote speaker was Prof. Dr. Gadis Sri Haryani from the Research Center for Limnology and Water Resources, National Research and Innovation Agency of the Republic of Indonesia (BRIN), Indonesia, who presented research about Migratory freshwater fish in Indonesia: Threats and conservation efforts. The second presenter was Dr. Robert Walsh from the Australian Water Life, Australia, who presented research about Discover the world of Micro-invertebrates. The third keynote speaker was Dr. Khamla Inkhavilay from the National University of Laos, Lao PDR, who presented Persistent Organic Pollutants in Wetland of Mekong Basin. The fourth speaker was Dr. Kwanraree Joy Sirikanchana from the Chulabhorn Research Institute, Thailand, who presented Microbial Source Tracking and Quantitative Microbial Risk Assessment for Sustainable Water Pollution Management. In addition, the four invited speakers and 66 general presenters split into four rooms for parallel discussions which covered the latest research on inland water ecosystems, including; (1) Biotic resources, biodiversity, and conservation; (2) System Dynamic of inland waters; (3) Applied technology for the management and pollution control; (4) Modelling, system information, decision support tool, disaster risk reduction; (5) Management, policies, regulation, education, social, economy, and culture. We highly appreciate the generous support from Research Centre for Limnology-BRIN (Indonesia), Australian Water Life (Australia), Chulabhorn Research Institute (Thailand), National University of Laos (Lao PDR), Southeast Asian Limnological Network (SEALnet), Advisory Board, Steering and Organizing committee and all presenters and participants. List of Committees, Advisory Board, Steering Committee, Scientific Committee, Organizing Committee, Documentation, all photos are available in this pdf.
22
Embree, Joanne. "It's Time for a National Immunization Strategy." Canadian Journal of Infectious Diseases 12, no. 4 (2001): 208–10. http://dx.doi.org/10.1155/2001/473852.
Full textAbstract:
Canada needs to develop and implement a national immunization strategy to provide optimal protection for vaccine-preventable diseases for children, adolescents and adults. Although the federal government has a mandate to ensure that access to health care is equitable across the country, it is the mandate of provincial governments to actually provide health care services. Thus, while the federal government makes recommendations for the optimal use of various vaccines through the publications of the National Advisory Committee on Immunization, the provincial governments must develop and fund their individual immunization programs. With a national immunization strategy that is endorsed by the federal and provincial governments, the following could occur: harmonization of childhood immunization schedules across the country; efficient introduction of new vaccines; the ability to enhance the monitoring of vaccine use and adverse events; and improvements in the ability to access readily vaccine products in the most cost effective manner. A national immunization strategy would also provide opportunities for vaccine and immunization research, and for improved education of health care providers and the general public.
23
Andrade-Gonzalez, Xavier, Anuhya Kommalapati, Allison M. Bock, Jacqueline Wang, Antoine Saliba, Javier Munoz, David J. Inwards, et al. "Influence of Treatment Facility Type and Annual Patient Volume on Overall Survival in Patients with Mantle Cell Lymphoma: A National Cancer Database Analysis." Blood 138, Supplement 1 (November 5, 2021): 1348. http://dx.doi.org/10.1182/blood-2021-151888.
Full textAbstract:
Abstract Introduction: Mantle cell lymphoma (MCL) is an uncommon hematological malignancy with an estimated incidence of 1 per 100,000 persons per year in the United States and represents only about 5% of all non-Hodgkin lymphomas. Several studies have shown that treatment at academic centers and a higher hospital case volume are associated with improved outcomes for uncommon hematological malignancies, probably due to increased provider expertise and access to novel therapies. Treatment of MCL can be complex given the heterogenous nature of the disease and a frequent need for autologous stem cell transplantation in eligible patients. However, the impact of treatment at an academic center and facility patient volume on the survival of patients with MCL has not been well studied in large cohorts. In this study, we utilized the National Cancer Database (NCDB) to investigate the impact of treatment at an academic center and treatment facility volume on the overall survival (OS) of patients with MCL. Methods: The NCDB was used to identify adult patients (≥ 18 years) with newly diagnosed MCL from 2004 through 2017. For facility patient volume analysis, patients were divided into groups based on the average number of new MCL patients seen annually: Tercile 1 [T1] (1-3 patients/year), Tercile 2 [T2] (4-5 patients/year) and Tercile 3 [T3] (≥6 patients/year). Treating centers were divided into Academic and Non-academic using the NCDB definitions. Academic centers were defined as centers that accessions more than 500 newly diagnosed cancer cases per year, participate in postgraduate medical education in at least four program areas including internal medicine and surgery and participates in cancer-related clinical trials. The primary endpoint was overall survival (OS). Survival analysis was performed using the Kaplan-Meier method and Cox hazards proportional model. Statistical analysis was performed using SPSS version 25. Results: We identified 22,752 patients with MCL during the study period. 9,484 (42%) patients were treated at academic centers and 13,070 (57%) were treated at non-academic centers. In terms of facility patient volume 10,948 patients (48%) were in the T1 group, 4,637 (20%) were in the T2 group and 7,166 (31%) were in the T3 group. No significant differences were found in baseline demographics (age, gender, race/ethnicity, comorbidity scores), socioeconomical variables (insurance type, median income, area of residence) and disease-related factors (B-symptoms, Ann Arbor stage) between patients treated academic vs nonacademic centers, or between patients in T1 vs T2 vs T3 groups. Notably, compared to lower volume facilities, T3 facilities were more likely to be academic centers (T3: 81% vs T2: 42% vs T1: 16%, p<0.001) . After a median follow-up of 3.4 years, the median overall survival (OS) was 5.6 years for the entire cohort. The median OS was inferior for patients treated at lower volume facilities (4.1 years for T1, 5.1 years for T2 and 9.0 years for T3, p<0.001) (Figure 1A). Similarly, the median OS was shorter for patients treated at non-academic centers vs academic centers (4.3 years vs 7.5 years respectively, p<0.001) (Figure 1B). In a multivariate analysis, treatment at a lower patient volume facility (Hazard ratio [HR] Q1= 1.26 [95%CI = 1.18-1.34]) and treatment at a non-academic center (HR = 1.1, 95%CI = 1.01-1.12) were both independent prognostic factors of inferior OS, after adjusting for demographics (age, gender, ethnicity, area of residence) and socioeconomic variables (income and insurance status). Conclusion: Patients with MCL treated at academic and higher volume facilities had a higher OS compared to patients treated at non-academic and lower volume facilities.. Additional research is needed to fully understand the mechanisms behind these differences. Patients with MCL may benefit from an early referral to academic and high-volume centers. Figure 1 Figure 1. Disclosures Munoz: Merck: Research Funding; Portola: Research Funding; Genentech: Research Funding; Incyte: Research Funding; Janssen: Research Funding; Seattle Genetics: Research Funding; Pharmacyclics/Abbvie, Bayer, Gilead/Kite Pharma, Pfizer, Janssen, Juno/Celgene, BMS, Kyowa, Alexion, Beigene, Fosunkite, Innovent, Seattle Genetics, Debiopharm, Karyopharm, Genmab, ADC Therapeutics, Epizyme, Beigene, Servier: Consultancy; Gilead/Kite Pharma, Kyowa, Bayer, Pharmacyclics/Janssen, Seattle Genetics, Acrotech/Aurobindo, Beigene, Verastem, AstraZeneca, Celgene/BMS, Genentech/Roche.: Speakers Bureau; Millennium: Research Funding; Pharmacyclics: Research Funding; Celgene: Research Funding; Physicians' Education Resource: Honoraria; Gilead/Kite Pharma: Research Funding; Kyowa: Honoraria; Bayer: Research Funding; Seattle Genetics: Honoraria; OncView: Honoraria; Targeted Oncology: Honoraria. Paludo: Karyopharm: Research Funding. Habermann: Seagen: Other: Data Monitoring Committee; Incyte: Other: Scientific Advisory Board; Tess Therapeutics: Other: Data Monitoring Committee; Morphosys: Other: Scientific Advisory Board; Loxo Oncology: Other: Scientific Advisory Board; Eli Lilly & Co.,: Other: Scientific Advisor. Nowakowski: Daiichi Sankyo: Consultancy; Zai Labolatory: Consultancy; TG Therapeutics: Consultancy; Blueprint Medicines: Consultancy; Nanostrings: Research Funding; MorphoSys: Consultancy; Kymera Therapeutics: Consultancy; Incyte: Consultancy; Ryvu Therapeutics: Consultancy; Kyte Pharma: Consultancy; Genentech: Consultancy, Research Funding; Roche: Consultancy, Research Funding; Celgene/Bristol Myers Squibb: Consultancy, Research Funding; Selvita: Consultancy; Curis: Consultancy; Karyopharm Therapeutics: Consultancy; Bantham Pharmaceutical: Consultancy. Wang: Novartis: Research Funding; LOXO Oncology: Membership on an entity's Board of Directors or advisory committees, Research Funding; TG Therapeutics: Membership on an entity's Board of Directors or advisory committees; Genentech: Research Funding; Eli Lilly: Membership on an entity's Board of Directors or advisory committees; MorphoSys: Research Funding; InnoCare: Research Funding; Incyte: Membership on an entity's Board of Directors or advisory committees, Research Funding.
24
Riekkinen, Mariya. "International Developments 2016: Economic, Social, and Cultural Life, Including Education and the Media, in the Context of European Minorities and from the Perspective of International Law." European Yearbook of Minority Issues Online 15, no. 01 (February 10, 2018): 51–89. http://dx.doi.org/10.1163/22116117_01501004.
Full textAbstract:
From the perspective of the rights of minorities in Europe, this section overviews international developments concerning economic and socio-cultural entitlements, including those related to education and the media. It is thematically structured around two clusters related to the minority rights: (a) cultural activities and facilities, including the media; and (b) economic and social life, including education, which are covered by the provisions of the European Charter for Regional and Minority Languages (ETS. No. 148). This review starts with an analysis of the 2016 developments at the UN level, and continues with an overview of advancements at the levels of the OSCE, the EU, and the Council of Europe. The adoption of the Thematic Commentary No. 4 “The Scope of Application of the Framework Convention for the Protection of National Minorities” by the Advisory Committee on the Framework Convention for the Protection of National Minorities (ACFC) is among the most important highlights.
25
Andrade-Gonzalez, Xavier, Allison M. Bock, Jacqueline Wang, Antoine Saliba, Javier Munoz, David J. Inwards, Jonas Paludo, Thomas M. Habermann, Grzegorz S. Nowakowski, and Yucai Wang. "Impact of Diagnosis-to-Treatment Interval on Overall Survival in Patients with Mantle Cell Lymphoma: A National Cancer Database Analysis." Blood 138, Supplement 1 (November 5, 2021): 3549. http://dx.doi.org/10.1182/blood-2021-151952.
Full textAbstract:
Abstract Introduction: The clinical presentation of mantle cell lymphoma (MCL) is heterogeneous, ranging from indolent disease that does not require immediate treatment to rapidly progressive disease that responds poorly to aggressive immunochemotherapy. Several small retrospective studies suggested that active surveillance or delayed treatment is feasible in select patients with an indolent disease course. A shorter diagnosis-to-treatment interval (DTI) is a strong predictor for inferior survival in patients with aggressive non-Hodgkin lymphomas such as diffuse large B-cell lymphoma (DLBCL) and peripheral T-cell lymphoma (PTCL), which likely correlates with an aggressive disease biology and clinical presentation. However, the impact of DTI on survival has not been well studied in patients with MCL. In this study, we utilized the National Cancer Database to investigate the feasibility of active surveillance or delayed treatment in patients with MCL and to explore the potential impact of DTI on survival of MCL patients requiring treatment. Methods: The National Cancer Database was used to identify adult patients (≥ 18 years) with MCL diagnosed from 2004 through 2017. Patients were divided into three groups based on their time to initial treatment: early treatment [ET] (treatment started within 3 months), delayed treatment [DT] (treatment started after 3 months) and surveillance [SUR] (watch and wait without treatment). Baseline clinical characteristics were compared between the 3 groups using Chi-square test. Survival analysis was performed using the Kaplan-Meier method and log-rank test. Statistical analysis was performed using SPSS version 25. Results: A total of 27,867 patients with newly diagnosed MCL were included in this study, 995 patients (4%) in the SUR group, 21,425 patients (77%) in the ET group, and 1,052 patients (4%) in the DT group. There were no major differences in the baseline characteristics among the three groups including demographics (age, sex, ethnicity), socioeconomic factors (annual income, insurance status, place of residence), comorbidity scores, and Ann Arbor stage. Compared to patients in the SUR and DT groups, patients in the ET group were more likely to have B symptoms (ET=27% vs DT=16% vs SUR=8%, p<0.001) and were less likely to be managed at an academic center (ET=40% vs DT=53% vs SUR= 51%, p<0.001) (Table 1). The median follow-up was 38.2 months for the entire cohort. There was a significant difference in OS among the three groups, with a median OS of 107 months (95% CI = 92.7-122.7) in the SUR group, 84.9 months (95% CI = 74.2-95.7) in the DT group, and 68.9 months (95% CI = 66.8-70.9) in the ET group (p=0.001) (Figure 1A). Among patients in the DT group, a shorter DTI was associated with a trend of inferior OS, with a median OS of 82 months (95% CI = 73.2-90.8) for those with a DTI of 3-12 months and not reached (95% CI not calculable) for those with a DTI > 12 months (p=0.095) (Figure 1B). Among the ET group, a shorter DTI was associated with shorter OS, with a median OS of 53 months (95% CI = 50.2-55.8) for patients with a DTI ≤ 15 days, 71.7 months (95% CI = 67.1-76.3) for those with a DTI of 16-30 days, and 87.1 months (95% CI= 82.8-91.4) for patients with a DTI of 31-90 days (p<0.001) (Figure 1C) Conclusion: In this retrospective analysis, patients with newly diagnosed MCL who were managed with an active surveillance strategy or delayed therapy had a better survival compared to patients who underwent early therapy. These findings validate the feasibility of delayed therapy in select patients with MCL. In patients who undergo early therapy, a shorter DTI is associated with an inferior survival outcome, mirroring findings in DLBCL and PTCL. A shorter DTI is likely associated with more aggressive disease biology and clinical presentation. Figure 1 Figure 1. Disclosures Munoz: Pharmacyclics/Abbvie, Bayer, Gilead/Kite Pharma, Pfizer, Janssen, Juno/Celgene, BMS, Kyowa, Alexion, Beigene, Fosunkite, Innovent, Seattle Genetics, Debiopharm, Karyopharm, Genmab, ADC Therapeutics, Epizyme, Beigene, Servier: Consultancy; Gilead/Kite Pharma, Kyowa, Bayer, Pharmacyclics/Janssen, Seattle Genetics, Acrotech/Aurobindo, Beigene, Verastem, AstraZeneca, Celgene/BMS, Genentech/Roche.: Speakers Bureau; Millennium: Research Funding; Janssen: Research Funding; Seattle Genetics: Research Funding; Pharmacyclics: Research Funding; Genentech: Research Funding; Incyte: Research Funding; Portola: Research Funding; Merck: Research Funding; Celgene: Research Funding; Gilead/Kite Pharma: Research Funding; Bayer: Research Funding; Physicians' Education Resource: Honoraria; Seattle Genetics: Honoraria; Targeted Oncology: Honoraria; OncView: Honoraria; Kyowa: Honoraria. Paludo: Karyopharm: Research Funding. Habermann: Seagen: Other: Data Monitoring Committee; Incyte: Other: Scientific Advisory Board; Tess Therapeutics: Other: Data Monitoring Committee; Morphosys: Other: Scientific Advisory Board; Loxo Oncology: Other: Scientific Advisory Board; Eli Lilly & Co.,: Other: Scientific Advisor. Nowakowski: Nanostrings: Research Funding; Blueprint Medicines: Consultancy; TG Therapeutics: Consultancy; Kymera Therapeutics: Consultancy; Incyte: Consultancy; Zai Labolatory: Consultancy; Daiichi Sankyo: Consultancy; Bantham Pharmaceutical: Consultancy; Karyopharm Therapeutics: Consultancy; Curis: Consultancy; Selvita: Consultancy; Ryvu Therapeutics: Consultancy; Kyte Pharma: Consultancy; Genentech: Consultancy, Research Funding; Roche: Consultancy, Research Funding; Celgene/Bristol Myers Squibb: Consultancy, Research Funding; MorphoSys: Consultancy. Wang: TG Therapeutics: Membership on an entity's Board of Directors or advisory committees; Eli Lilly: Membership on an entity's Board of Directors or advisory committees; MorphoSys: Research Funding; Genentech: Research Funding; Novartis: Research Funding; LOXO Oncology: Membership on an entity's Board of Directors or advisory committees, Research Funding; Incyte: Membership on an entity's Board of Directors or advisory committees, Research Funding; InnoCare: Research Funding.
26
Gugliucci, Marilyn. "GSA STUDENT CHAPTERS: THE BEGINNING AND HOW TO START A CHAPTER AT YOUR INSTITUTION." Innovation in Aging 7, Supplement_1 (December 1, 2023): 183. http://dx.doi.org/10.1093/geroni/igad104.0603.
Full textAbstract:
Abstract The Gerontological Society of America (GSA) Student Chapter pilot project was approved by the GSA Board of Directors in December 2020. A GSA representative committee was identified where all GSA member groups were represented, including the selection of three ESPO members who applied to participate. Within a year, a GSA Student Chapter Handbook was written by the committee and reviewed by a GSA Student Advisory Panel (ESPO members who applied and agreed to serve). With the support of the GSA leadership and staff, nine higher education institutions (HEIs) volunteered to pilot a GSA Student Chapter (eight in the U.S. and one in Portugal) during the 2022-23 academic year. The first part of this session will provide information on how to create, implement, and operate a GSA Student Chapter at your HEI. The second part of this session will focus on health professions programs and integrating GSA Student Chapters with other national chapters. With a strong support system and mentoring system within ESPO, health professions programs may benefit from having student chapters integrate from various national organizations. These may provide advancement in learning skills, attitudes and knowledge, along with an extensive network of fellow students and practitioners to support their pre-clinical and clinical health professions education. This enhancement for Student Chapters, GSA with other organization chapters provides national and possibly international organizational connections/networking that will serve students throughout their careers.
27
Duncan, Pamela W. "One Grip a Little Stronger." Physical Therapy 83, no. 11 (November 1, 2003): 1014–21. http://dx.doi.org/10.1093/ptj/83.11.1014.
Full textAbstract:
Abstract Pamela W Duncan, PT, PhD, FAPTA Dr Duncan has actively participated in and contributed to physical therapist practice, physical therapist professional education, professional preparation of other health care providers, national policy development related to rehabilitation after stroke and aging, and scientific investigation. She has served several government appointments and provides leadership within several organizations. She served as co-chair of the Consensus Panel on Establishing Guidelines for Stroke Rehabilitation for the Agency for Health Care Policy, Research, and Education. She was a panel member on the National Institutes of Health's Total Hip Replacement Consensus Conference and served on the Strategic Planning Group for Stroke Research for the National Institute of Neurological Disorders and Stroke. She recently was appointed to serve on the Steering Committee of the Department of Education's National Institute on Disability and Rehabilitation Research and is currently on the Executive Leadership Council of the American Stroke Foundation and the Advisory Committee of the Canadian Stroke Network. She has served on committees and panels for the American Heart Association and was president of APTA's Neurology section. Dr Duncan's research activities focus on geriatric rehabilitation, stroke rehabilitation, and health outcomes measurement. She developed the Functional Reach Test, used to assess balance in older adults. In the past 20 years, she has received $13 million in research awards as principal investigator or co-investigator from agencies such as the National Institutes of Health, National Institute on Aging, American Heart Association, Department of Veteran's Affairs, and National Center for Medical Rehabilitation Research and from multiple private funding sources. Dr Duncan has disseminated her research findings in more than 80 peer-reviewed articles in 20 different journals, and she has written a book and 12 book chapters. Dr Duncan's work has influenced the care and rehabilitation of patients in the United States and worldwide. Physical therapy education programs across the country incorporate her findings and professional vision into the preparation of the next generation of physical therapists. APTA has awarded Dr Duncan the Marian Williams Award for Research in Physical Therapy, the Catherine Worthingham Fellowship Award, and the Mary McMillan Scholarship Award. She has also received research awards from the APTA Neurology Section, Sports Physical Therapy Section, and Section on Geriatrics, as well as a service award from the Neurology Section. She is an elected fellow of the Stroke Council of the American Heart Association and has given 8 invited lectureships at universities across the United States.
28
Mavroudis, Constantine, James K. Kirklin, and William M. DeCampli. "Incremental History of the Congenital Heart Surgeons’ Society (2014-2018)." World Journal for Pediatric and Congenital Heart Surgery 9, no. 6 (October 15, 2018): 668–76. http://dx.doi.org/10.1177/2150135118800305.
Full textAbstract:
The history of the first 41 years of the Congenital Heart Surgeons Society (CHSS) was recorded in 2015 which chronicled the metamorphosis of a small informal meeting into a mature organization with bylaws, officers, committees, funded research, the Kirklin-Ashburn Fellowship, and a vision to become the premier organization of congenital heart surgery in North America. Chief among these transformations was the implementation and development of the CHSS Data Center. Member participation, fellowship education, and significant outcomes research have been the hallmark of the CHSS. This incremental historical review highlights continued CHSS sentinel advances. Fifty-three CHSS Data Center manuscripts have been published. Citation scores (number of literature citations that each manuscript has accrued) have been collated and analyzed by cohort study. The average citation score for all manuscripts was 75.4 ± 76.3 (range: 1-333). The Kirklin/Ashburn Fellowship continues to thrive with academic achievements and generous contributions to the endowment. The World Journal of Pediatric and Congenital Heart Surgery has been adopted as the official organ of the CHSS. A Past President’s Dinner has been inaugurated serving as a senior advisory committee to the Executive Council. Toronto Work Weekends continue. Congenital Heart Surgeons Society growth has accrued to 159 active members and 82 institutional members. Future considerations include the size, content, and duration of the annual meeting; the potential for increased membership; and political penetrance into national cardiothoracic governing organizations regarding committee appointments, executive council representation, and education initiatives. Congenital Heart Surgeons Society has achieved numerous advances during this incremental period.
29
Flanders, James R. "How Much of the Content in Mathematics Textbooks Is New?" Arithmetic Teacher 35, no. 1 (September 1987): 18–23. http://dx.doi.org/10.5951/at.35.1.0018.
Full textAbstract:
The importance of textbooks to the U.S. mathematics curriculum cannot be overstated. The recent rejection by the California State Board of Education of all fourteen text series submitted for adoption illustrates the public perception of the importance of textbooks. Begle (1973) pointed to data from the National Longitudinal Study of Mathematical Achievement to emphasize the important influence textbooks have on student learning, citing evidence that students learn what is in the text and do not learn topics not covered in the book. The National Advisory Committee on Mathematical Education (1975) acknowledged the importance of textbooks as guides for teachers. Fey (1980) emphasized the important influence of texts and pointed out that text content is usually not ba ed on research. Investigators at the Insti tute for Research on Teaching offer evidence that, at the very least, texts are important exercise sources (see Porter et al. 1986). The overall picture is that to a great extent the textbook defines the content of the mathematics that is taught in U.S. schools.
30
Joseph, Nisha, Kathryn T. Maples, Kevin Hall, Vikas A. Gupta, Larry H. Boise, Leonard T. Heffner, Madhav V. Dhodapkar, et al. "Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients." Blood 138, Supplement 1 (November 5, 2021): 1616. http://dx.doi.org/10.1182/blood-2021-151161.
Full textAbstract:
Abstract Background: Despite significant advances in therapeutic options for multiple myeloma (MM) patients, there is an ongoing need to identify effective treatment strategies in the relapsed space. The efficacy of daratumumab, pomalidomide and dexamethasone (DPD) in relapsed and/or refractory patients has been demonstrated in clinical trials, but there is limited data at first relapse in a real world setting. Here, we present a retrospective analysis utilizing our institutional data of multiple myeloma patients treated with DPD at first relapse at the Winship Cancer Institute of Emory University. Methods: Ninety relapsed and/or refractory myeloma (RRMM) patients were identified who had received only one prior line of therapy and subsequently treated with DPD at first relapse. Dose-adjustments were made based on the treating physician's discretion and patient tolerability. Demographic and outcomes data for the patients were obtained from our IRB approved myeloma database and responses were evaluated per IMWG Uniform Response Criteria. Results: The median age of this cohort was 61.9 years (range, 38-85). Other notable patient characteristics include: M/F 44.4%/55.6%; W/AA/Asian 50%/46.7%/3.3%; ISS I/II/III 28.9%/31.1%/20%; Isotype IgG/IgA/FLC 62.2%/17.8%/16.7%; standard risk/high risk 21.1%/52.2%. High risk disease was defined as the presence of t(4;14), t(14;16), del(17p), and/or complex karyotype. A total of 69 patients (76.7%) underwent autologous stem cell transplant (ASCT) upfront after attaining at least a partial response with induction therapy. The most common induction regimen was RVD (78.9%). 81.1% of patients received maintenance therapy, with 50.5% receiving single-agent lenalidomide maintenance and 72.2% receiving a lenalidomide-based maintenance regimen (RVD: 8 pts; Rd: 4 pts; IRD: 7 pts, KRD: 1 pt). With a median follow up of 72 months, the median OS from diagnosis was 158.6 months (95% CI 126.7-190.5) for the entire cohort. The median PFS from time of initiation of DPD was 15.6 months (95% CI 9.9-21.2), and the median OS from time of initiation of DPD was 41.3 months. For high risk vs standard risk patients, the mPFS from time of initiation of DPD was 7.2 months (95% CI 3.6-10.7) vs 17.6 months (95% CI 10.9-24.3), respectively. Median PFS2 in patients <2 years and >2 years from transplant was 8.6 months vs NR, respectively. Conclusions: These results illustrate the activity of DPD at first relapse in a predominantly len-refractory RRMM cohort of patients with impressive long-term outcomes. This benefit was particularly demonstrated in patients with time to relapse of >2 years post-transplant. Figure 1 Figure 1. Disclosures Joseph: GSK: Honoraria; BMS: Research Funding; Takeda: Research Funding; Karyopharm: Honoraria. Boise: AstraZeneca: Honoraria, Research Funding; AbbVie/Genentech: Membership on an entity's Board of Directors or advisory committees. Hofmeister: BlueBird Bio: Other: Non-CME speaker; Aptitude Health: Other: Non-pharma speaker for education, research, marketing; Verascity: Other: Non-pharma speaker for education, research, marketing; TRM Oncology: Other: Non-pharma speaker for education, research, marketing; DAVA Oncology: Other: Non-pharma speaker for education, research, marketing; Medscape: Other: Non-pharma speaker for education, research, marketing; Amgen: Other: Non-CME speaker; BMS: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Philips Gilmore: Other: CME speaker; Non-pharma speaker for education, research, marketing; BioAscend: Other: CME speaker; Imbrium: Membership on an entity's Board of Directors or advisory committees; Myeloma360: Membership on an entity's Board of Directors or advisory committees; Genzyme: Membership on an entity's Board of Directors or advisory committees; Takeda: Other: Local PI of CST; Oncolytics: Other: National PI for CST; PI or co-PI IST; Oncopeptides: Membership on an entity's Board of Directors or advisory committees; Karyopharm: Membership on an entity's Board of Directors or advisory committees, Other: Local PI of CST; Janssen: Membership on an entity's Board of Directors or advisory committees, Other: Local PI of CST; Nektar Therapeutics: Membership on an entity's Board of Directors or advisory committees, Other: Local PI of CST; BMS/Celgene: Other: National PI for CST; PI or co-PI IST; Local PI of CST; Sanofi: Other: National PI for CST; PI or co-PI IST; Ohio State University: Current Employment, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees, Other: IP rights, Patents & Royalties. Kaufman: Incyte, TG Therapeutics: Membership on an entity's Board of Directors or advisory committees; Sutro, Takeda: Research Funding; Roche/Genetech, Tecnopharma: Consultancy, Honoraria; Fortis Therapeutics: Research Funding; Heidelberg Pharma: Research Funding; BMS: Consultancy, Research Funding; Amgen: Research Funding; Tecnofarma SAS, AbbVie: Honoraria; Incyte, celgene: Consultancy; Janssen: Honoraria; Novartis: Research Funding; Genentech, AbbVie, Janssen: Consultancy, Research Funding. Lonial: Abbvie: Consultancy, Honoraria; Janssen: Consultancy, Honoraria, Research Funding; TG Therapeutics: Membership on an entity's Board of Directors or advisory committees; Takeda: Consultancy, Honoraria, Research Funding; BMS/Celgene: Consultancy, Honoraria, Research Funding; GlaxoSmithKline: Consultancy, Honoraria, Research Funding; Merck: Honoraria; AMGEN: Consultancy, Honoraria. Nooka: GlaxoSmithKline: Consultancy, Other: Travel expenses; Amgen: Consultancy, Research Funding; Oncopeptides: Consultancy; Janssen Oncology: Consultancy, Research Funding; Sanofi: Consultancy; Karyopharm Therapeutics: Consultancy; Takeda: Consultancy, Research Funding; Bristol-Myers Squibb: Consultancy; Adaptive technologies: Consultancy.
31
Dick, Thomas. "The Continuing Calculator Controversy." Arithmetic Teacher 35, no. 8 (April 1988): 37–41. http://dx.doi.org/10.5951/at.35.8.0037.
Full textAbstract:
To use or not to use calculator in the elementary school classroom? That seems to be a question as contro-versial now as it was in 1975 when the National Advisory Committee on Mathematical Education offered the following advice: “beginning no later than the end of the eighth grade, a calculator should be available for each mathematics student during each mathematics class. Each student should be permitted to use the calculator during all of his or her mathematical work including tests.” In An Agenda for Action (1980), the National Council of Teachers of Mathematics (NCTM) recommended that “mathematics programs must take full advantage of the power of calculators and computers at all grade levels.” This recommendation was reaffirmed by the NCTM in a position statement (Calculators in the Mathematics Classroom, April 1986) with the further call “that publishers, authors, and test writers integrate the use of the calculator into their mathematics materials at all levels.”
32
Gilbert, J. R., and G. J. Brooks. "A study of the food eaten in conventional Royal Navy submarines." Journal of The Royal Naval Medical Service 71, no. 1 (March 1985): 19–24. http://dx.doi.org/10.1136/jrnms-71-19.
Full textAbstract:
SummaryA detailed study of the food eaten at sea in three conventional submarines was performed. The composition of the ships’ companies’ diet was taken from forms which detailed daily transfers from store to galley. The constituents were analysed by computer using a database drawn from The Composition of Foods (HMSO).From this investigation it is evident that during the period studied (62 days at sea in total) in comparison with the national average the submariners’ daily diet contains 50-100% excess salt, fat, sugar, protein and energy. Due to this general excess of consumption, the daily fibre intake was found to be greater than the national average but less than advised by the National Advisory Committee on Nutrition Education (NACNE).In view of the present consensus, as expressed in the NACNE report, on what constitutes a healthy diet, it was felt that the food consumed in the sample would contribute in the short term to loss of overall fitness and predispose in the long term to disease. This has implications for the efficiency of the Submarine Service if the sample was truly representative.
33
Bernal-Mizrachi, Leon, Ajay K. Nooka, Leonard Heffner, Craig E. Cole, Jing C. Ye, Ravi Vij, Craig C. Hofmeister, et al. "Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial, PINR)." Blood 138, Supplement 1 (November 5, 2021): 2758. http://dx.doi.org/10.1182/blood-2021-153922.
Full textAbstract:
Abstract Introduction: Proteasome inhibitors (PI) and immunomodulatory drugs have become the backbone of therapy for multiple myeloma (MM). The oral boron-containing selective and reversible proteasome inhibitor ixazomib has shown to induce deep and durable responses (Kumar RK et la, Blood 2016. 128(20):2415-2422). Triplets containing ixazomib, has shown to be more efficacious than doublet regimens in the relapse setting (Moreau P, et al. N Engl J Med 2016. 374:1621-1634).However, to date, there is not companion diagnostics capable of predicting PI response. We have recently discovered that MM patients resistant to PI lack of the ankyrin (ANK) and death domain (DD) present in the 3'-end of NFKB2. Loss of NFKB2 3'end frequently resulted from a structural rearrangements. We found that NFKB2-ANK and -DD are crucial at initiating bortezomib's apoptotic signal by facilitating caspase-8 activation (unpublished data). Based on this findings, we designed this study to examine the efficacy of NFKB2 break apart FISH to predict the response to ixazomib and dexamethasone (Id) vs. ixazomib, lenalidomide and dexamethasone (IRd) in early relapse MM patients. Methods: In this phase 2 biomarker-driven open-label trial, relapsed patients with <4 lines of therapy were randomized to ixazomib 4 mg weekly 3 of 4 weeks and 40 mg weekly dexamethasone vs. Id plus 25 mg of lenalidomide daily days 21/28, based on the status of NFKB2 rearrangement in plasma cells. Patients were screened for NFKB2 rearrangement detected by NFKB2 break apart FISH. Patients without NFKB2 rearrangement received Id and patients with NFKB2 rearrangement were subsequently randomized in a 1:1 fashion to receive Id or IRd. The primary endpoint is to compare the response rate (MR or better) of Id or IRd at 4 cycles according to the rearrangement status of NFKB2 Results: At the moment of the interim analysis, 60 patients have achieved 4 cycles of treatment. All treatment groups (NFKB2 FISH [-] Id, n=27, NFKB2 FISH [+] Id, n=20 and IRd, n=19) received a median of 2 prior lines of therapy. A trend to higher ORR was observed in NFKB2 FISH negative treated with Id compared with NFKB2 FISH positive (41% CI:58%-97% vs. 30% CI:8%-60%, P=0.4, target p-value goal 0.15), including significantly higher rates of ≥ very good partial response, ≥ partial response, ≥ minimal response (15%, 25%, 15% vs. 4%, 25%, 10%, respectively). ORR for IRd arm is for now 57% CI:27%-80%. Interestingly, >G3 treatment related adverse events were higher in Arm A (15%) and Arm C (13%) vs Arm B (0%). The most common (≥10%) ≥ grade 3 include URI/pneumonia 16% and diarrhea 12% in Id NFKB2 FISH negative vs. neutropenia 18% and diarrhea (10%) in the IRd NFKB2 FISH positive arm. Treatment discontinuations only occurred in 3 NFKB2 FISH positive Id treated patient (13%). Conclusion: Interim analysis demonstrates a trend higher efficacy and ≥G3 toxicity of ixazomib with dexamethasone in MM patients with negative NFKB2 break-apart FISH compared to those with a positive test. Efficacy and toxicity of the triplet regimen are comparable to what is seen in the Tourmaline 1 trial. This study is registered clinicaltrials.gov# NCT02765854 Disclosures Bernal-Mizrachi: Kodikaz Therapeutic Solutions: Consultancy, Current holder of individual stocks in a privately-held company, Patents & Royalties; Bristol Myers Squibb: Consultancy, Membership on an entity's Board of Directors or advisory committees; Takeda Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Winship Cancer Institute of Emory University: Current Employment; Bigene: Membership on an entity's Board of Directors or advisory committees. Nooka: Takeda: Consultancy, Research Funding; Janssen Oncology: Consultancy, Research Funding; GlaxoSmithKline: Consultancy, Other: Travel expenses; Sanofi: Consultancy; Bristol-Myers Squibb: Consultancy; Amgen: Consultancy, Research Funding; Oncopeptides: Consultancy; Adaptive technologies: Consultancy; Karyopharm Therapeutics: Consultancy. Ye: Alexion, AstraZeneca Rare Disease: Other: Study investigator. Vij: BMS: Research Funding; Takeda: Honoraria, Research Funding; Sanofi: Honoraria, Research Funding; BMS: Honoraria; GSK: Honoraria; Oncopeptides: Honoraria; Karyopharm: Honoraria; CareDx: Honoraria; Legend: Honoraria; Biegene: Honoraria; Adaptive: Honoraria; Harpoon: Honoraria. Hofmeister: Ohio State University: Current Employment, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees, Other: IP rights, Patents & Royalties; Medscape: Other: Non-pharma speaker for education, research, marketing; DAVA Oncology: Other: Non-pharma speaker for education, research, marketing; TRM Oncology: Other: Non-pharma speaker for education, research, marketing; Verascity: Other: Non-pharma speaker for education, research, marketing; Aptitude Health: Other: Non-pharma speaker for education, research, marketing; BlueBird Bio: Other: Non-CME speaker; Amgen: Other: Non-CME speaker; Celgene: Membership on an entity's Board of Directors or advisory committees; BMS: Membership on an entity's Board of Directors or advisory committees; Philips Gilmore: Other: CME speaker; Non-pharma speaker for education, research, marketing; BioAscend: Other: CME speaker; Imbrium: Membership on an entity's Board of Directors or advisory committees; Myeloma360: Membership on an entity's Board of Directors or advisory committees; Genzyme: Membership on an entity's Board of Directors or advisory committees; Takeda: Other: Local PI of CST; Oncolytics: Other: National PI for CST; PI or co-PI IST; Oncopeptides: Membership on an entity's Board of Directors or advisory committees; Karyopharm: Membership on an entity's Board of Directors or advisory committees, Other: Local PI of CST; Janssen: Membership on an entity's Board of Directors or advisory committees, Other: Local PI of CST; Nektar Therapeutics: Membership on an entity's Board of Directors or advisory committees, Other: Local PI of CST; BMS/Celgene: Other: National PI for CST; PI or co-PI IST; Local PI of CST; Sanofi: Other: National PI for CST; PI or co-PI IST. Rushton: KSL: Current Employment. Lonial: Merck: Honoraria; TG Therapeutics: Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Honoraria; Takeda: Consultancy, Honoraria, Research Funding; GlaxoSmithKline: Consultancy, Honoraria, Research Funding; AMGEN: Consultancy, Honoraria; BMS/Celgene: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding. Kaufman: Incyte, celgene: Consultancy; Genentech, AbbVie, Janssen: Consultancy, Research Funding; Tecnofarma SAS, AbbVie: Honoraria; Heidelberg Pharma: Research Funding; Janssen: Honoraria; Novartis: Research Funding; Incyte, TG Therapeutics: Membership on an entity's Board of Directors or advisory committees; Fortis Therapeutics: Research Funding; BMS: Consultancy, Research Funding; Amgen: Research Funding; Roche/Genetech, Tecnopharma: Consultancy, Honoraria; Sutro, Takeda: Research Funding.
34
Hillman, William A. "The Role of the Federal Government in Adapted Physical Education." Adapted Physical Activity Quarterly 3, no. 2 (April 1988): 124–26. http://dx.doi.org/10.1123/apaq.3.2.124.
Full textAbstract:
The development of adapted physical education over the past 20 years has been significantly influenced by the federal government through legislative statutes. A predecessor to Public Law 94-142 that may well have had the most impact on handicapped children was Public Law 90-170, which provided the foundation for adapted physical education by allowing monies for training research and development. This legislation established committees and conferences that brought together national figures to serve as advisory consultants. Programmatic support from the federal government has led to the training of many teachers and much published research in adapted physical education.
35
Doucette, Kimberley, Allison Taylor, Bryan Chan, Xiaoyang Ma, Jaeil Ahn, David H. Vesole, and Catherine Lai. "Impact of Treating Facility on Overall Survival and Treatment in Multiple Myeloma (MM) Using National Cancer Database (NCDB)." Blood 138, Supplement 1 (November 5, 2021): 2996. http://dx.doi.org/10.1182/blood-2021-153021.
Full textAbstract:
Abstract Introduction: Prior studies have shown poorer outcomes in Black and Hispanic patients and in patients with lower median household income and education 1-5. In MM, we hypothesize that facility affiliation and case volume affects overall survival (OS) and rates of frontline treatment (including chemotherapy, immunotherapy, autologous stem cell transplant [ASCT] and palliative care). Methods: This is a retrospective analysis of 174,551 MM patients in the NCDB database, over the age of 18 years, between 2004-2016. Facility types include community cancer programs, comprehensive community cancer programs, academic/research cancer programs and integrated network cancer programs. High volume facilities had new MM cases per year ≥ 99 th percentile, and all other facilities were classified as low volume. Multivariable analyses used Cox proportional hazard analysis for OS and logistic regression for use of treatment, adjusted for age, sex, race, Hispanic origin, education, great circle distance, CCI score, and type of county (depending on population size). Kaplan-Meier method was used to estimate median OS, and the log rank test was used to compare OS across predictor variables. Results: The median age was 67 years (range 18-90) with 55% males, and 76% White vs 20% Black. In academic/research cancer programs, the median OS in high volume centers was 75.5 mo vs 50.2 mo in low volume centers (p<0.01). In community cancer programs, the median OS in high volume centers was 55.2 mo vs 35.5 mo in low volume centers (p<0.01). In multivariable analyses, the OS was higher in academic/research cancer programs vs community cancer programs (hazard ratio of 0.87 p<0.01). There was no significant difference in OS at integrated network cancer programs or comprehensive community cancer programs vs community cancer programs. The odds of utilizing chemotherapy were higher in academic/research cancer programs compared to community cancer programs (p<0.01 for both), whereas the odds of receiving palliative care were similar between both facility types (p=0.25). The odds of utilizing ASCT were higher in all facilities when compared to community cancer programs (p<0.01). The odds of utilizing palliative care were higher at integrated network cancer programs and comprehensive community cancer programs compared to community cancer programs (p<0.01 for both). Facilities with low volume of cases had significantly lower odds of utilizing chemotherapy, immunotherapy and ASCT when compared to high volume facilities; however had significantly increased odds of receiving palliative care. Discussion: Our results show that academic/research cancer programs with high volumes have the best OS in MM. Additionally, academic/research cancer programs are more likely to give chemotherapy, immunotherapy, and ASCT, but less likely to give palliative care. We theorize that academic/research cancer programs with a high volume of cases likely have increased resources, which optimizes outcomes. Given that ~25% of patients with MM die in the first year 6, there is a recognized need to identify strategies to improve early outcomes in patients treated at community cancer programs and low volume facilities. Figure 1 Figure 1. Disclosures Lai: Jazz Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees; Daiichi-Sankyo: Consultancy, Membership on an entity's Board of Directors or advisory committees; Astellas: Speakers Bureau; Macrogenics: Consultancy, Membership on an entity's Board of Directors or advisory committees; Agios: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Jazz Pharma: Speakers Bureau; Genentech: Consultancy, Membership on an entity's Board of Directors or advisory committees.
36
Alese, Theodora, Benjamin G. Barwick, Vikas A. Gupta, Nisha Joseph, Craig C. Hofmeister, Mala Shanmugam, Jonathan L. Kaufman, et al. "BRAF Mutations and Inflammatory Gene Expression in Myeloma Cells from Patients with Renal Dysfunction." Blood 138, Supplement 1 (November 5, 2021): 1624. http://dx.doi.org/10.1182/blood-2021-154092.
Full textAbstract:
Abstract Introduction: Multiple Myeloma (MM), the second most common blood cancer, is a clonal disease of long-lived plasma cells (PC) that is currently incurable. Symptomatic myeloma-defining events include hyper calcemia, renal dysfunction, anemia, and bone disease (CRAB criteria). Renal dysfunction is primarily due to free light chain (FLC) precipitation with uromodulin in the distal tubules resulting in light chain cast nephropathy (LCCN). Renal dysfunction may have a negative impact on patient outcomes as it can influence the ability to optimally treat patients, and in some may result in hemodialysis dependence. Therefore, understanding the factors that can contribute to renal dysfunction could allow for early intervention to prevent associated morbidity. Methods: To determine whether certain proteins or genetic mutations in MM patients are associated with renal failure, we analyzed data from the Multiple Myeloma Research Foundation's CoMMpass Study (NCT01454297, Interim Analysis 16) using creatinine levels as a surrogate for renal dysfunction (>176 μmol/L indicates renal failure). We correlated creatinine with other measures of renal dysfunction (BUN), serum protein levels (total protein, M-protein, IgG, IgA, IgM, IgL-kappa, IgL-lambda), as well as structural changes including t(11;14), t(12;14), t(14;16), t(14;20), t(6;14), t(8;14), hyperdiploidly, 1q21 gains and 17p13 loss as determined by whole genome sequencing (WGS). We used whole exosome sequencing (WES) data to assess if common mutations (KRAS, NRAS, BRAF, DIS3, FAM46C) were associated with renal dysfunction. The numbers in each comparison differed based on the availability of WGS (structural events: 621 vs. 96) or WES (SNVs: 1003 vs. 119). To study gene expression we focused on the patients with the highest and lowest creatinine levels (70/group). Since there was a sex bias in these groups we included a covariate for sex to determine gene expression changes independent of sex. Finally, we analyzed RNAseq analysis for expression of light chain variable regions to determine if there was an association of light chain usage with renal dysfunction. Results: We initially correlated BUN, serum protein levels and structural events with creatinine levels, but only found a significant correlation with BUN levels (Pearson R=0.7275, P=<0.0001, N=816). We next performed a contingency analysis comparing genetic events in patients with creatinine >176 μmol/L versus those <176 μmol/L. While there were no differences in structural events between those with normal vs. elevated creatinine, we did observe a significant increase in BRAF mutations in patients with high creatinine (Fisher's exact test, P=0.0093). We also observed a trend towards significance with KRAS mutations (Fisher's exact test P=0.0930). We examined light chain variable region usage but found no association with high creatinine levels. We expanded this analysis to all genes, and found 110 genes differentially expressed with renal dysfunction, which were enriched for genes involved in inflammatory responses (AIF1, LY96, LYVE1, MPEG1, SELL1, STAB1, TNFRSF12A) and metabolism (COX7A2, FOLR2, MT-ND1, MT-ND3). Conclusions: Our data are consistent with previous studies with respect to the lack of association of renal dysfunction with serum proteins and translocations. However, we observed interesting associations with BRAF mutations and a trend with KRAS mutations, suggesting a role in disease pathogenesis beyond driving tumorigenesis. Additionally, we detected expression changes with several genes involved in inflammatory responses. We cannot conclude if this is due to inflammation related to acute kidney disease or if the myeloma plasma cells expressing these genes are more likely to produce FLC that result in LCCN. Finally, we did not observe a variable chain usage bias, however our study is limited to expression and therefore points to the likelihood that somatic hypermutation plays an important role in whether a light chain can lead to renal disease. Taken together, these data suggest the presence of genetic and biological differences in myeloma cells associated with renal dysfunction and provide insights into identifying patients that could develop renal disease. ACKNOWLEDGEMENTS This work was supported through the STEP-UP HS program from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, R25DK113659 Disclosures Joseph: GSK: Honoraria; BMS: Research Funding; Takeda: Research Funding; Karyopharm: Honoraria. Hofmeister: Sanofi: Other: National PI for CST; PI or co-PI IST; BMS/Celgene: Other: National PI for CST; PI or co-PI IST; Local PI of CST; Nektar Therapeutics: Membership on an entity's Board of Directors or advisory committees, Other: Local PI of CST; Janssen: Membership on an entity's Board of Directors or advisory committees, Other: Local PI of CST; Karyopharm: Membership on an entity's Board of Directors or advisory committees, Other: Local PI of CST; Oncopeptides: Membership on an entity's Board of Directors or advisory committees; Oncolytics: Other: National PI for CST; PI or co-PI IST; Takeda: Other: Local PI of CST; Genzyme: Membership on an entity's Board of Directors or advisory committees; Myeloma360: Membership on an entity's Board of Directors or advisory committees; Imbrium: Membership on an entity's Board of Directors or advisory committees; BioAscend: Other: CME speaker; Philips Gilmore: Other: CME speaker; Non-pharma speaker for education, research, marketing; BMS: Membership on an entity's Board of Directors or advisory committees; Celgene: Membership on an entity's Board of Directors or advisory committees; Amgen: Other: Non-CME speaker; BlueBird Bio: Other: Non-CME speaker; Aptitude Health: Other: Non-pharma speaker for education, research, marketing; Verascity: Other: Non-pharma speaker for education, research, marketing; TRM Oncology: Other: Non-pharma speaker for education, research, marketing; DAVA Oncology: Other: Non-pharma speaker for education, research, marketing; Medscape: Other: Non-pharma speaker for education, research, marketing; Ohio State University: Current Employment, Current holder of individual stocks in a privately-held company, Current holder of stock options in a privately-held company, Membership on an entity's Board of Directors or advisory committees, Other: IP rights, Patents & Royalties. Kaufman: Genentech, AbbVie, Janssen: Consultancy, Research Funding; Incyte, celgene: Consultancy; Tecnofarma SAS, AbbVie: Honoraria; Amgen: Research Funding; BMS: Consultancy, Research Funding; Fortis Therapeutics: Research Funding; Heidelberg Pharma: Research Funding; Incyte, TG Therapeutics: Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria; Novartis: Research Funding; Roche/Genetech, Tecnopharma: Consultancy, Honoraria; Sutro, Takeda: Research Funding. Lonial: AMGEN: Consultancy, Honoraria; TG Therapeutics: Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Honoraria; Takeda: Consultancy, Honoraria, Research Funding; GlaxoSmithKline: Consultancy, Honoraria, Research Funding; Merck: Honoraria; Janssen: Consultancy, Honoraria, Research Funding; BMS/Celgene: Consultancy, Honoraria, Research Funding. Nooka: Takeda: Consultancy, Research Funding; GlaxoSmithKline: Consultancy, Other: Travel expenses; Amgen: Consultancy, Research Funding; Karyopharm Therapeutics: Consultancy; Bristol-Myers Squibb: Consultancy; Adaptive technologies: Consultancy; Sanofi: Consultancy; Oncopeptides: Consultancy; Janssen Oncology: Consultancy, Research Funding. Boise: AstraZeneca: Consultancy, Research Funding; Abbvie: Consultancy.
37
Ball, Marion, and Judith Douglas. "Informatics in Professional Education." Methods of Information in Medicine 28, no. 04 (October 1989): 250–54. http://dx.doi.org/10.1055/s-0038-1636794.
Full textAbstract:
Abstract:The University of Maryland at Baltimore (UMAB) is a professional school campus, including schools of Dentistry, Law, Medicine, Nursing, Pharmacy, Graduate Studies, and Social Work and Community Planning. In late 1987, UMAB convened a Task Force on Informatics, intended to support the campus as it worked to become a Centre of Excellence for Informatics. The Task Force reviewed the current computing environment at UMAB and the individual schools. In assessing the state ofthe art in informatics, its work was supplemented by the formation of external advisory committees of national and international informaticians. Deliberations proceeded according to a methodology designed to develop factual databases and to generate consensus. The Task Force report, which is excerpted in the following paper, established a tiered taxonomy of competencies; defined the three levels; and set forth program models for the two higher levels. Special note was made of the programs in ´nursing and dental informatics newly established at UMAB. The report concluded with three recommendations, each with detailed action points identified.
38
Peden, Amy E., Dennis Alonzo, Faye McMillan, Tich Phuoc Tran, Catherine Hawke, Rebecca Ivers, and Richard C. Franklin. "Co-Designing a Farm Safety Gamified Educational Resource With Secondary School Students and Their Teachers: Qualitative Study Protocol." International Journal of Qualitative Methods 22 (January 2023): 160940692311563. http://dx.doi.org/10.1177/16094069231156345.
Full textAbstract:
Unintentional injuries are a leading cause of preventable harm among adolescents. Adolescents also experience an increased risk of farm injury, and in Australia, injury-related farm fatalities among adolescents have remained largely unchanged over the past two decades. A third of all incidents involve farm visitors, indicating the need for population-level safety information. This project uses qualitative data to inform a co-design process with adolescents, and their teachers, to develop a game-based farm injury prevention online educational resource. This protocol describes the multi-phase co-design project. Focus group discussions regarding farm injury prevention will be held with students (Year 7 & 8; ∼12–14 years of age) and teachers at high schools with an agricultural focus across two Australian states. Inductive thematic analysis of discussion transcripts, and analysis of farm injury data, will inform the development of the modules and content of the game. User experience testing of the prototype will form the final phase of the project. This process is supported by a Stakeholder Advisory Group, which includes representatives of youth farming organisations, agricultural educators, and national child safety organisations. This group will assist in interpretation and dissemination of findings and promoting the resultant educational resource in schools. Ethical approval has been granted by the University of New South Wales Human Research Ethics Committee. Results will be disseminated through peer-reviewed publications, mass media releases, academic conferences, and the agricultural education sector in Australia via the stakeholder advisory group. This study will provide useful insights into co-designing injury prevention resources for adolescents using gamification and result in a co-designed farm injury prevention educational resource for schools and the general community via mobile and web-based applications.
39
Harris, Lauren, Daniel Gilmore, Anne Longo, and Brittany N. Hand. "Short report: Patterns of US federal autism research funding during 2017–2019." Autism 25, no. 7 (March 25, 2021): 2135–39. http://dx.doi.org/10.1177/13623613211003430.
Full textAbstract:
In 2017, the Interagency Autism Coordinating Committee, a federal advisory panel consisting of autism researchers and community members, recommended that funders of autism research prioritize research projects on: (1) treatments/interventions, (2) evidence-based services, and (3) lifespan issues. We sought to describe research funding since this recommendation was made. We searched the databases of the three largest federal funders of autism research in the United States (National Institutes of Health, Department of Education, and Centers for Disease Control and Prevention) for grants awarded during 2017–2019. We categorized grants as follows: autism screening and diagnosis, biology, risk factors, treatments and interventions, services, lifespan issues, or infrastructure and surveillance. We found that funding patterns remained largely consistent during 2017–2019. Biological research received a relative majority of funding (32.59%), followed by treatments and interventions (22.87%). While given higher funding priority by the Interagency Autism Coordinating Committee’s recent budget recommendation, fewer funds were awarded to research areas like services (5.02%) and lifespan issues (2.51%), indicating a misalignment between funding patterns and the Interagency Autism Coordinating Committee budget recommendation. These findings emphasize the need for autism research funding to align with the Interagency Autism Coordinating Committee budget recommendations to best meet the needs of the autism community, particularly autistic younger, middle-aged, and older adults. Lay abstract In 2017, an advisory board consisting of autism researchers and community members recommended that funders of autism research prioritize research projects on: (1) treatments/interventions, (2) evidence-based services, and (3) lifespan issues. To describe funding in these areas since this recommendation was made, we searched the databases of the three largest federal funders of autism research in the United States. We found that the largest portion of federal funding during 2017–2019 was awarded to research on the biology of autism (32.59%) and treatments and interventions for autism (22.87%). Less funds were awarded to research areas that are high funding priorities by the Interagency Autism Coordinating Committee budget recommendation including services (5.02%) and lifespan issues (2.51%). Our findings emphasize that autism research funding is not consistent with the Interagency Autism Coordinating Committee budget recommendation to increase funding particularly to services and lifespan issues. We recommend that funding patterns should shift to better align with these priorities so that autism research may better serve the needs of the autism community.
40
Pressley, Margaret, and Rebecca Henry. "A Personal Journey toward Teaching Success." American String Teacher 44, no. 2 (May 1994): 69–72. http://dx.doi.org/10.1177/000313139404400227.
Full textAbstract:
Margaret Pressley is well known in the Pacific Northwest as a teacher of gifted pre-college violinists and as an enabler of conservatory-level music education in Seattle. Attending the University of Washington, with a major in violin performance, she chose a career in violin pedagogy, which has spanned 30 years. Pressley has built a highly successful class of continuously prize-winning students, who are eagerly sought by conservatories. She is the founder and director of the Pressley Conservatory of Music in Seattle. Pressley is a lecturer at Western Washington University and is also on the faculty of the Indiana University Summer String Academy, a member of the advisory board of the Seattle Young Artist Music Festival and the National Music Teachers Association Competition String Repertoire Committee, and string chair for the Washington State Music Teachers Association. She was named ASTA's 1994 Washington State Studio Teacher of the Year.
41
Frampton, Phil. "Bring back orphanages - bring back attachments." DECP Debate 1, no. 144 (September 2012): 32–37. http://dx.doi.org/10.53841/bpsdeb.2012.1.144.32.
Full textAbstract:
Phil Frampton was born in 1953 in a ‘Magdalene laundry’ in Cornwall and abandoned to the care system until the age of18. His memoirThe Golly in the Cupboard(2004) on being mixed race and brought up in care, was followed by his BBC programme of the same name, which won the 2005 Race in the Media Award for radio documentaries. An experienced keynote speaker and author of three travel books, Phil is a freelance journalist, broadcaster and research consultant. He has written for The Independent, The Guardian, The Daily Mail, Big Issue, and journals around the world. Phil was a member of the Cabinet Office Advisory Group on the Education of Young People in Care, a Parliamentary Select Committee Witness ιegaιdìng Abuse of Children in Care, founding Chair of Care Leavers Association (2000-2003) and in 2008, was shortlisted to become a national Director of OFSTED.
42
Walz, Bruce J., Richard A. Bissell, Brian Maguire, and James A. Judge. "Vaccine Administration by Paramedics: A Model for Bioterrorism and Disaster ResponsePreparation." Prehospital and Disaster Medicine 18, no. 4 (December 2003): 321–26. http://dx.doi.org/10.1017/s1049023x00000558.
Full textAbstract:
AbstractThe events of 11 September 2001 have had a profound effect on disaster planning efforts in the United States. This is true especially in the area of bioter-rorism. One of the major tenets of bioterrorism response is the vaccination of at-riskpopulations. This paper investigates the efficacy of training emergency medical services paramedics to administer vaccines in public health settings as preparation for and response to bioterrorism events and other disaster events.The concept of vaccination administration by specially trained paramedics is not new. Various programs to provide immunizations for emergency services personnel and at-risk civilian populations have been reported.Vaccination programs by paramedics should follow the guidelines of the National Vaccine Advisory Committee of the Centers for Disease Control and Prevention (CDC). Thispaper compares the seven standards of the CDC guidelines to routine paramedic practice and education. It is concluded that paramedics are adequately trained to administer vaccines. However, specific training and protocols are needed in the areas of administrative paperwork and patient education. A proposed outline for a paramedic-training program is presented.
43
Walz, Bruce J., Richard A. Bissell, Brian Maguire, and James A. Judge. "Vaccine Administration by Paramedics: A Model for Bioterrorism and Disaster Response Preparation." Prehospital and Disaster Medicine 18, no. 4 (December 2003): 321–26. http://dx.doi.org/10.1017/s1049023x00001278.
Full textAbstract:
AbstractThe events of 11 September 2001 have had a profound effect on disaster planning efforts in the United States. This is true especially in the area of bioter-rorism. One of the major tenets of bioterrorism response is the vaccination of at-riskpopulations. This paper investigates the efficacy of training emergency medical services paramedics to administer vaccines in public health settings as preparation for and response to bioterrorism events and other disaster events.The concept of vaccination administration by specially trained paramedics is not new. Various programs to provide immunizations for emergency services personnel and at-risk civilian populations have been reported.Vaccination programs by paramedics should follow the guidelines of the National Vaccine Advisory Committee of the Centers for Disease Control and Prevention (CDC). Thispaper compares the seven standards of the CDC guidelines to routine paramedic practice and education. It is concluded that paramedics are adequately trained to administer vaccines. However, specific training and protocols are needed in the areas of administrative paperwork and patient education. A proposed outline for a paramedic-training program is presented.
44
Leggat, Sandra. "Australian Health Review call for papers." Australian Health Review 30, no. 4 (2006): 417. http://dx.doi.org/10.1071/ah060417.
Full textAbstract:
The Editor of Australian Health Review invites contributions for an upcoming issue on health professional education. Submission deadline: 6 February 2007 It is expected that tertiary education and research for health professionals will be the focus of substantial change over the next couple of years. The health professional workforce has been the subject of recent studies in Australia and New Zealand. The New Zealand Health Workforce Advisory Committee has focused on ensuring an effective strategic framework and outlined seven principles comprising equity and appropriateness, strategic and sustainable supply, healthy workplaces, collaborative practice, effective education, stakeholder involvement and information and monitoring.1 In Australia, the Productivity Commission made strong recommendations directed at improving health professional education to enhance coordination, reduce practice barriers and address shortages of health professionals. 2 To help inform policy and practice, Australian Health Review is looking to publish feature articles, research papers, case studies and commentaries related to health professional education. Potential topic areas include: � Addressing health workforce challenges � Multidisciplinary professional practice and interdisciplinary education � Management education and clinician managers � Evidence-based education � Sector-based approaches to education and training � Partnerships and social change � Impact of national education and research policy on health professional education. Submissions related to international programs with lessons for Australia and New Zealand will also be welcomed. Submissions can be short commentaries of 1000 to 2000 words, or more comprehensive reviews of 2000 to 4000 words. Please consult the AHR Guidelines for Authors for information on formatting and submission.
45
Othman, Jad, Usman Afzal, Ruebina Amofa, Michael J. Austin, Alex Bashford, Edward Belsham, Jennifer Byrne, et al. "Gilteritinib for Relapsed Acute Myeloid Leukaemia with FLT3 Mutation during the COVID-19 Pandemic: Real World Experience from the UK National Health Service." Blood 138, Supplement 1 (November 5, 2021): 1254. http://dx.doi.org/10.1182/blood-2021-150169.
Full textAbstract:
Abstract Background Early data suggest that patients undergoing salvage chemotherapy for relapsed or refractory (R/R) acute myeloid leukaemia (AML) have poor outcomes if infected with SARS-CoV-2, and nosocomial transmission has been a major problem worldwide. Gilteritinib is effective in R/R FLT3 mutated AML, is significantly less immunosuppressive and does not require hospital admission, however at the start of the pandemic this was not yet approved for routine use in all countries. In the United Kingdom, the National Health Service (NHS) made gilteritinib available as an emergency measure from late April 2020 to patients aged >16y with R/R FLT3 mutated AML, with the aim of reducing both mortality and healthcare resource use. We report a health-system-wide real world data collection for toxicity and patient outcomes across 27 NHS Hospitals. Methods Each patient was registered on a central NHS database, with clinicians certifying that their patient met the above criteria. Anonymised data were retrospectively collected by treating physicians. Gilteritinib dose, duration and toxicity information was requested for the first 4 cycles of therapy. Response definitions were as per European Leukaemia Network (ELN) guidelines. A total of 81 patients have been registered on the scheme, with outcomes reported here for those with follow-up information at a data cut on 1st August 2021. Results Fifty patients were included with a median age of 59y (range 19 - 77) and 50% male. The majority (83%) had an ECOG performance status of 0-1. AML was secondary to a previous haematological disorder in 12%, therapy-related in 4% and de novo in the remaining 84%. The disease was refractory to the last therapy in 38%. Most patients had previously received 1 (65%) or 2 (33%) lines of therapy, including intensive chemotherapy in a majority (86%). A FLT3 inhibitor had previously been administered to 45% and 35% were post allogeneic transplant. The FLT3 mutation was an internal tandem duplication (ITD) in 80% and tyrosine kinase domain (TKD) mutation in 22%. NPM1 mutations were detected in 34%. Next-generation sequencing results were available for 94% of patients, with mutations in IDH1 or IDH2 in 12.5%, ASXL1 in 2%, RUNX1 in 21% and no TP53 mutations. Patients spent a median 3.5 days in hospital in cycle 1, 0 days in cycles 2 and 3 and 1 day in cycle 4. In cycles 1, 2, 3 and 4, the median number of days of grade 4 neutropenia was 18, 7, 7.5, and 6.5 respectively, and the grade 4 thrombocytopenia was 2, 7, 0.5 and 0.5. The composite complete remission (CR) / CR with incomplete haematological recovery (CRi) rate was 27%. MRD data is being collected. The best response was morphological leukaemia free state (MLFS) in 4%, partial remission (PR) in 25% and refractory disease in 38%. The rate of combined CR/CRi did not differ in those with previous exposure to FLT3 inhibitors (23% vs 32%, p=0.6) or with past allogeneic transplant (29% vs 27%, p=0.3). There were no CR/CRi in patients with adverse cytogenetic risk. Median follow-up was 10.5 months (95%CI 7.3 - 12.3) with median overall survival (OS) 6.7 months (95%CI 4.5 - not reached). Mortality at day 30 was 0% and day 60 was 14%. 12-month overall survival was 38%. Patients who achieved a CR/CRi had a 12-month OS of 83%, and for PR this was 35%. Survival did not differ in those with previous FLT3 inhibitor exposure (HR 1.0, p>0.9) or allogeneic transplant (HR 0.63, p=0.3). Seven patients (14%) so far have been bridged with gilteritinib to allogeneic transplant. Conclusion Our data demonstrate that gilteritinib is well tolerated and clinically active in adults with relapsed FLT3 mutated AML. Importantly, during the COVID-19 pandemic, its availability has permitted the great majority of treatment to be delivered as an outpatient with significant resource saving at a time of critically constrained inpatient resources. Patients who achieve CR/CRi have good short-term outcomes and are able to proceed to a potentially curative allogeneic stem cell transplant. Figure 1 Figure 1. Disclosures Belsham: Celgene: Other: meeting attendance; Abbvie: Other: meeting attendance. Byrne: Incyte: Honoraria. Khan: Abbvie: Honoraria; Astellas: Honoraria; Takeda: Honoraria; Jazz: Honoraria; Gilead: Honoraria; Novartis: Honoraria. Khwaja: Pfizer: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Jazz Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Astellas: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Latif: Kite: Consultancy, Honoraria, Speakers Bureau; Jazz: Consultancy, Honoraria; Daiichi Sankyo: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; Amgen: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria; Astellas: Consultancy, Honoraria, Speakers Bureau; Takeda UK: Speakers Bureau. Loke: Amgen: Honoraria; Daichi Sankyo: Other: Travel Support; Janssen: Honoraria; Novartis: Other: Travel Support; Pfizer: Honoraria. Munisamy: Jazz Pharmaceuticals: Speakers Bureau; Roche: Speakers Bureau. Murthy: Abbvie: Other: support to attend educational conferences.. Smith: Daiichi Sankyo: Speakers Bureau; Pfizer: Speakers Bureau; ARIAD: Honoraria. Craddock: Novartis Pharmaceuticals: Other: Advisory Board ; Celgene/BMS: Membership on an entity's Board of Directors or advisory committees, Research Funding. Dillon: Amgen: Other: Research support (paid to institution); Astellas: Consultancy, Other: Educational Events , Speakers Bureau; Menarini: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees, Other: Session chair (paid to institution), Speakers Bureau; Pfizer: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: educational events; Jazz: Other: Education events; Shattuck Labs: Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Research Support, Educational Events.
46
Kovas, Yulia, Eduard V. Galajinsky, Michel Boivin, Gordon T. Harold, Alice Jones, Jean-Pascal Lemelin, Yu Luo, et al. "The Russian School Twin Registry (RSTR): Project PROGRESS." Twin Research and Human Genetics 16, no. 1 (December 13, 2012): 126–33. http://dx.doi.org/10.1017/thg.2012.133.
Full textAbstract:
The Russian School Twin Registry (RSTR) was established in 2012, supported by a grant from the Government of the Russian Federation. The main aim of the registry is to contribute to Progress in Education through Gene-Environment Studies (PROGRESS). The formation of the registry is ongoing and it is expected that most schools in the Russian Federation (approximately 50,000 schools) will contribute data to the registry. With a total of 13.7 million students in Grades 1–11 (ages 7–18), the potential number of twin pairs exceeds 100,000. Apart from the large sample size and its representative nature, the RSTR has one unique feature: in collaboration with the International Advisory Committee to the Registry, genetically sensitive cross-cultural investigations are planned, aided by the use of the common assessment instruments. Other strengths of the registry include the assessment of a large sample of non-twin school children, including those studying in the same classes as the twins in the registry. It is hoped that the RSTR will provide an important research platform for national and international educationally relevant research.
47
Hermawan, Agung, Jaya Maulana, Teguh Irawan, and Muhammad Fatih Izzul Maula. "Pendampingan Prosedur Keselamatan Kerja pada UMKM Produksi Furniture CV Rumah Menyala di Kabupaten Batang." Jurnal Pengabdian Nasional (JPN) Indonesia 5, no. 2 (May 20, 2024): 485–91. http://dx.doi.org/10.35870/jpni.v5i2.877.
Full textAbstract:
The furniture industry is a strategic commodity supporting national foreign exchange. Indonesia has great potential in developing this industry, supported by the availability of raw materials such as wood, rattan, and bamboo and an abundant workforce. However, workplaces in this sector, both formal and informal, have various potential hazards that can affect the health and safety of workers. This research aims to provide stimulus in the form of Personal Protective Equipment (PPE) and work safety signs to CV Rumah Menyala furniture MSMEs in Tegalsari Village, Kandeman, Batang, to improve worker safety and health. This activity includes the formation of an Occupational Safety and Health Advisory Committee (P2K3), education regarding hazard and risk mapping, and preparing work safety SOP documents. The activity results show increased worker awareness regarding the importance of using PPE and managing work safety. However, ongoing efforts are still needed to implement work safety SOPs with discipline. In this way, it is hoped that the risk of occupational diseases and work accidents can be minimized to increase worker productivity
48
Solway, Erica. "Involvement in State and Federal Aging Policy." Innovation in Aging 4, Supplement_1 (December 1, 2020): 684. http://dx.doi.org/10.1093/geroni/igaa057.2385.
Full textAbstract:
Abstract The fourth speaker is Dr. Erica Solway. Dr. Solway will discuss her experience working in policy at the federal level as a Health and Aging Policy Fellow and a policy advisor with the U.S. Senate Committee on Health, Education, Labor, and Pensions Subcommittee on Primary Health and Aging and in her current involvement in policy-relevant research at the state and national level at the University of Michigan Institute for Healthcare Policy & Innovation. Dr. Solway is a senior project manager forthe evaluation of the Healthy Michigan Plan, Michigan’s Medicaid expansion program, and is also an associate director of the University of Michigan National Poll on Healthy Aging.
49
Khalatbari, Shokoufeh, Sandra Taylor, Davis Marry Sammel, Margaret Stedman, Joycelynne Palmer, and Shelby Smith. "158 Building a National Network for Collaborative Quantitative Staff." Journal of Clinical and Translational Science 8, s1 (April 2024): 48. http://dx.doi.org/10.1017/cts.2024.153.
Full textAbstract:
OBJECTIVES/GOALS: Quantitative Staff are an essential workforce for biomedical research. While faculty can engage with peers locally and through national organizations, similar opportunities are limited for staff and often do not meet their unique needs and interests. Creating a professional community is valuable for supporting and developing this workforce. METHODS/STUDY POPULATION: We established the Quantitative Scientific Staff National Network (QS2N2) with the mission to provide professional development and networking opportunities, and to serve as an information resource and advocate through the fostering of community among staff quantitative analysts at any career stage. The initial membership outreach was to all Biostatistics, Epidemiology, and Research Design (BERD) programs through members of ACTS BERD Special Interest Group (SIG). We created a Leadership Team and an Advisory Board consisting of staff and faculty biostatisticians with experience working as or managing staff to govern the network. A Core Planning Committee consisting of 15 members guides planning, implementation, and execution of network activities as operationalized through subcommittees. RESULTS/ANTICIPATED RESULTS: The network currently has 131 members from over 30 health science institutions. Subcommittees focused on Education and Training, Membership, Communication and Web Development, and Mentoring were created and are developing events, programs and infrastructure to further the network’s mission. Network events such as webinars will be offered quarterly; with our first event planned for Nov 3rd. Expansion and maturation of QS2N2 will be done through regular remote meetings where members can connect with peers at other institutions, engage in career development activities, and attend technical seminars. Additional membership outreach will seek to connect with staff in government and private sectors. DISCUSSION/SIGNIFICANCE: Knowledgeable, highly skilled collaborative analysts (e.g., biostatisticians, data scientists) are an essential workforce in clinical and translational science and health research centers.The QS2N2 will support professional development, engagement and growth of this critical workforce which is necessary to advance quality research.
50
Harcombe, Zoe. "US dietary guidelines: is saturated fat a nutrient of concern?" British Journal of Sports Medicine 53, no. 22 (August 14, 2018): 1393–96. http://dx.doi.org/10.1136/bjsports-2018-099420.
Full textAbstract:
US public health dietary advice was announced by the Select Committee on Nutrition and Human needs in 1977 and was followed by UK public health dietary advice issued by the National Advisory Committee on Nutritional Education in 1983. Dietary recommendations in both cases focused on reducing dietary fat intake; specifically to (i) reduce overall fat consumption to 30% of total energy intake and (ii) reduce saturated fat consumption to 10% of total energy intake. The recommendations were an attempt to address the incidence of coronary heart disease. These guidelines have been reiterated in the Dietary Guidelines for Americans since the first edition in 1980. The most recent edition has positioned the total fat guideline with the use of ‘Acceptable Macronutrient Distribution Ranges’. The range given for total fat is 20%–35% and the AMDR for saturated fat is given as <10%—both as a percentage of daily calorie intake. In February 2018, the Center for Nutrition Policy and Promotion announced ‘The US Departments of Agriculture and Health and Human Services currently are asking for public comments on topics and supporting scientific questions to inform our development of the 2020–2025 Dietary Guidelines for Americans’. Public comments were invited on a number of nutritional topics. The question asked about saturated fats was: ‘What is the relationship between saturated fat consumption (types and amounts) during adulthood and risk of cardiovascular disease?’ This article is a response to that question.